[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-ovarian-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-ovarian-insufficiency":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,45,71,94,124,150,176,203,225,254,278,297,320,346,370],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100581549","phase-3-hormone-replacement-therapy-in-adolescents-with-premature-ovarian-insufficiency-100581549",false,"NCT06851754","Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","* INCLUSION CRITERIA:\n\nInclusion Criteria for POI Participants\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n1. Individuals aged 11-19 years, inclusive, at the time of enrollment.\n2. Diagnosis of premature ovarian insufficiency.\n3. Documentation of one elevated serum FSH measurement greater than the testing laboratory's upper reference range (for age\u002FTanner stage).\n4. Identify as female (i.e., sex assigned at birth)\n5. Negative pregnancy test.\n\nInclusion Criteria for Healthy Volunteers:\n\n1. Individuals aged 11-19 years.\n2. Identify as female (i.e., sex assigned at birth)\n3. Negative pregnancy test.\n4. Absence of known chronic disease\n\nEXCLUSION CRITERIA:\n\nMale participants are excluded from both study groups (POI and Healthy Volunteers) as POI affects only the female reproductive system, while pregnant participants are not eligible to have DXA or HRpQCT imaging for safety reasons.\n\nExclusion Criteria for POI participants:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. POI in the setting of Turner syndrome.\n2. Patients who screened positive for celiac disease.\n3. Receipt of any medications including HRT determined by the investigator to affect bone metabolism 3 months prior to enrollment.\n4. Any medical condition determined by the investigator to affect bone health will be excluded.\n5. Presence of a medical, psychiatric, or social condition which, in the opinion of the investigator, would place undue burden on the subject, NIH resources, or increase risk of participation.\n6. Report of sexual activity but refusal to use a copper intrauterine device or double barrier forms of contraception during the study.\n\nExclusion Criteria for Healthy Volunteers:\n\nFor healthy volunteers, all exclusion criteria will apply as for POI participants except for number 1.",true,"FEMALE","11 Years","19 Years",{"count":20,"type":21},185,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Background:\n\nPremature ovarian insufficiency (POI) is a condition in which women under the age of 40 years have absent or irregular menstrual cycles. POI can cause infertility, signs of menopause, osteoporosis, and other symptoms. Hormone replacement therapy (HRT) is a treatment that gives women extra hormones, such as estrogen and progesterone. HRT works well in adult women. Researchers want to find the most effective doses and regimens for adolescents.\n\nObjective:\n\nTo monitor the effects of HRT on adolescents with POI.\n\nEligibility:\n\nFemale adolescents aged 11 to 19 years diagnosed with POI. Healthy volunteers are also needed.\n\nDesign:\n\nAll participants will have clinic visits every 6 months for 2 years. Each visit may last 2 days. Each visit may include:\n\nBlood and urine tests.\n\nA test of their heart function.\n\nA test to measure the stiffness of their blood vessels. Participants will lie flat with a blood pressure cuff on a leg and a meter on the neck while the cuff inflates.\n\nA test of their grip strength. Participants will squeeze a handheld device as hard as they can.\n\nTwo scans to measure bone density. For one, participants will lie on a table while a scanner passes along their body. For the other, participants will sit in a chair and insert their forearm, then their lower leg, into a scanner.\n\nA test to measure skin pigmentation. Participants' skin will be touched lightly with a device.\n\nAn optional visual exam of the vagina. Some vaginal fluid may also be collected with a cotton swab\u002Fcytobrush.\n\nParticipants with POI will receive HRT. They will be given estrogen patches and progesterone pills.",[27],"Premature Ovarian Insufficiency",[27,29,30,31],"Hormone Replacement Therapy","Adolescents","Bone Health","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2025-07-17",{"date":40,"type":21},"2031-12-31",{"name":42,"class":43},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100521279","a-multicenter-observational-study-on-the-development-and-health-effects-of-premature-ovarian-insufficiency-100521279","NCT06067529","A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency","POI","Women with POI\n\n1. Inclusion Criteria 1.1 Age at Diagnosis: Less than 40 years of age. 1.2 Diagnosis of POI: Met one of the following diagnostic criteria based on ESHRE guidelines: Spontaneous POI: Oligomenorrhea or amenorrhea for at least 4 months, combined with elevated FSH levels (\\> 25 IU\u002FL) on two occasions at least 4 weeks apart.\n\n   Iatrogenic POI: Documented history of bilateral oophorectomy, or ovarian failure resulting from chemotherapy or radiotherapy.\n\n   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and complete long-term follow-up assessments.\n2. Exclusion Criteria 2.1 Current Pregnancy or Lactation: Women who were pregnant or breastfeeding at the time of enrollment.\n\n2.2 Severe Systemic Conditions: Presence of severe somatic or psychiatric diseases (e.g., active malignancy not related to POI, severe heart\u002Frenal failure, or cognitive impairment) that would preclude adherence to the study protocol or long-term follow-up.\n\nControl\n\n1. Inclusion Criteria:\n\n   1.1 Age: 18-50 years. 1.2 Menstrual History: Regular menstrual cycles (21-35 days) for the past 12 months.\n\n   1.3 Consent: Willingness to participate, provide biological samples, and provide written informed consent.\n2. Exclusion Criteria:\n\n2.1 Physiological Status: Pregnancy, breastfeeding, or clinical perimenopause\u002Fpostmenopause.\n\n2.2 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.\n\n2.3 Iatrogenic \\& Toxic Factors: Prior ovarian surgery (e.g., cystectomy), chemotherapy, or radiotherapy.\n\n2.4 Systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, or hematological diseases, or malignancy.\n\n2.5 Genetic \\& Familial Background: First-degree relatives with POI or early menopause (\\\u003C 45 years). Family history of hereditary diseases. 2.6 Medication: Use of hormonal drugs or contraceptives within the last 6 months.\n\nOvarian Surgery group\n\n1. Inclusion Criteria:\n\n   1.1 Age: 18-60 years. 1.2 Patients with ovarian surgery: women scheduled to undergo ovarian surgery for gynecological disease.\n\n   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent.\n2. Exclusion Criteria:\n\n2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.\n\n2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months.\n\n2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease.\n\n2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology.\n\n2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment.\n\nOophorectomy group\n\n1. Inclusion Criteria:\n\n   1.1 Age: 45-65 years. 1.2 Patients with oophorectomy: women scheduled to undergo oophorectomy due to gynecological diseases and met criteria for being menopausal.\n\n   1.3 Menopausal status: at least 12 consecutive months of amenorrhea without other medical causes.\n\n   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent.\n2. Exclusion Criteria:\n\n2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.\n\n2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months.\n\n2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease 2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology.\n\n2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment.","10 Years","65 Years",{"count":55,"type":21},1080,"OBSERVATIONAL","Premature ovarian insufficiency (POI) refers to the occurrence of ovarian hypofunction in women before the age of 40, which seriously affects women's overall health and quality of life. However, there is currently insufficient understanding of the risk factors, pathogenesis, short-term and long-term health effects of POI, and the health effects of the disease, and there is a lack of high-quality evidence to support clinical diagnosis and treatment decisions. This study intends to construct a hospital-based multi-center POI case-control and prospective special disease cohort, after baseline assessment and follow-up monitoring, collect disease characteristics, lifestyle, social psychology, environmental and occupational exposure, biological samples and other data, aiming to observe POI The natural occurrence, progression and health impact of POI, clarify the risk factors of POI, evaluate the impact of POI on women's health and disease risk, and discuss the benefits, risks and options of HRT for POI patients. The results of this study will deepen and expand the understanding of the occurrence and development of POI and its short-term and long-term health effects, provide high-level evidence for optimizing POI prevention, diagnosis and treatment strategies, and establish a long-term management system, laying the foundation for interventional research.",[27],[27],"2026-05-25",{"date":62,"type":36},"2026-05-28",{"date":64,"type":36},"2023-10-10",{"date":66,"type":21},"2026-12-31",{"name":68,"class":69},"Women's Hospital School Of Medicine Zhejiang University","OTHER",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":15,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100639161","genetic-variants-in-idiopathic-premature-ovarian-insufficiency-100639161","NCT07587853","Genetic Variants in Idiopathic Premature Ovarian Insufficiency","Investigation of Pathogenic Variants in DNA Repair and Meiotic Genes Associated With Ovarian Reserve and Folliculogenesis in Idiopathic Premature Ovarian Insufficiency Using Whole Exome Sequencing: A Case-Control Study","Inclusion Criteria:\n\nFor the idiopathic premature ovarian insufficiency group:\n\n* Women aged 18 to 39 years.\n* Spontaneous amenorrhea or marked menstrual irregularity lasting at least 4 months.\n* Serum FSH level greater than 25 IU\u002FL. In cases of diagnostic uncertainty, FSH measurement may be repeated after 4 to 6 weeks.\n* Diagnosis of idiopathic premature ovarian insufficiency, with no known chromosomal abnormality, FMR1 premutation, defined syndromic genetic diagnosis, or iatrogenic cause.\n* Willingness to participate in the study and ability to provide written informed consent.\n\nFor the control group:\n\n* Women aged 18 to 39 years.\n* Regular menstrual cycles.\n* Age-appropriate normal ovarian reserve findings, including FSH and AMH values within age-appropriate reference ranges and, when available, appropriate antral follicle count.\n* No known history of infertility, premature ovarian insufficiency, or early menopause.\n* No history of gonadotoxic treatment or ovarian surgery.\n* Willingness to participate in the study and ability to provide written informed consent.\n\nExclusion Criteria:\n\nFor both groups:\n\n* Known chromosomal abnormality, such as Turner syndrome or structural X chromosome abnormality.\n* FMR1 premutation carrier status.\n* Previously defined syndromic genetic diagnosis.\n* Active malignancy.\n* History of gonadotoxic chemotherapy or pelvic radiotherapy.\n* Iatrogenic ovarian damage or iatrogenic premature ovarian insufficiency after ovarian surgery.\n* Clear autoimmune, endocrine, or other clinical condition that may explain secondary amenorrhea.\n* Refusal to provide informed consent or request to withdraw study data.\n* Insufficient DNA sample quality or inability to complete genetic analysis for technical reasons.\n\nAdditional exclusion criteria for the control group:\n\n* Known history of infertility, premature ovarian insufficiency, or early menopause.\n* Ovarian reserve findings below the expected range for age.\n* Previous gonadotoxic treatment or ovarian surgery.","18 Years","39 Years",{"count":81,"type":21},100,"Premature ovarian insufficiency is a condition in which ovarian function decreases or is lost before the age of 40 years. In many patients, the underlying cause remains unexplained. This prospective observational case-control study aims to investigate pathogenic and likely pathogenic genetic variants in DNA repair and meiotic genes related to ovarian reserve and folliculogenesis in women with idiopathic premature ovarian insufficiency.\n\nThe study will include women younger than 40 years with idiopathic premature ovarian insufficiency and age- and ethnicity-matched control participants with normal ovarian function. Clinical and reproductive data will be collected, and a peripheral blood sample will be obtained from each participant for whole exome sequencing. The frequency of pathogenic or likely pathogenic variants will be compared between the case and control groups. No investigational drug, device, or treatment intervention will be administered.",[27],"NOT_YET_RECRUITING","2026-05-14",{"date":87,"type":36},"2026-05-19",{"date":89,"type":21},"2026-06-10",{"date":91,"type":21},"2028-06-10",{"name":93,"class":69},"Abdurrahman Hamdi İnan",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":15,"sex":16,"minAge":78,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100375326","ventricular-repolarization-in-patients-with-premature-ovarian-insufficiency-qtiop-100375326","NCT04167033","Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QTIOP)","Study of Ventricular Repolarization in Patients With Premature Ovarian Insufficiency and Influence of Estrogen-progestin Replacement Therapy","QTIOP","Inclusion Criteria:\n\nPatients with POI\n\n* Patient aged 18 to 41 years\n* Patient with POI diagnostic criteria (FSH \\>25UI\u002Fl twice at intervals of a few weeks) with amenorrhea\n* No hormone treatment interacting with the gonadotropic axis for at least one month before inclusion\n* Patient who has signed informed consent\n* Patient affiliated to a social security system\n\nHealthy volunteers (including POI control group)\n\n* Healthy women, aged 18 to 40 years, age-matched (+\u002F- 5 years), and by BMI class (BMI\\\u003C18, 18-25, 25-30, 30-35, 35-40, \\>40) compared to women with BPI\n* Women with regular cycles of 26 to 32 days\n* Women who has signed an informed consent form\n* Patient affiliated to a social security system\n\nExclusion Criteria:\n\nPatients with POI\n\n* Patient on HRT during the 1st evaluation\n* Pregnant or breastfeeding woman\n* Treatment regimen known to lengthen QT or act on ventricular repolarization\n* Cardiac history in particular cardiac rhythm disorder\n* Diabetes\n* Patient on AME (unless derogation from affiliation),\n* Severe renal insufficiency (MDRD \\\u003C30ml\u002Fmin\u002Fm²)\n\nHealthy volunteers (including POI control group)\n\n* Diabetes or any chronic disease (including cardiovascular and endocrine)\n* Pregnant or breastfeeding woman\n* Hormonal contraceptive treatment in progress or stopped less than 3 months ago\n* Chronic treatment affecting the duration of QTc\n* Woman under AME (unless affiliation derogation)","40 Years",{"count":104,"type":21},120,[106],"NA","Ventricular repolarization, measured by corrected QT interval (QTc), is influenced by sex hormones. A QTc above 460msec predisposes to the risk of \"torsades-de-pointes\"(TdP). The investigators have recently shown that estradiol determines an increase in QTc elongation and progesterone shortens it. In addition, high gonadotropin levels (FSH or LH) are associated with QTc prolongation. Hypergonadotropic hypogonadisms (low progesterone and high gonadotropins) are therefore hormonal situations that promote QTc prolongation. Premature ovarian insufficiency (POI) is one of them. Its management is based on the prescription of hormone replacement therapy (HRT). Epidemiological studies have shown that these patients would be at increased risk of cardiovascular mortality. Our team is interested in the effect of this pathological hormonal situation and its HRT on ventricular repolarization in order to define whether this is a population at risk for long QTc.",[27],[110,111,112,113],"Premature ovarian insufficiency","QTc","Torsade de pointe","Hormone replacement therapy","2025-12-02",{"date":116,"type":36},"2025-12-09",{"date":118,"type":36},"2021-04-14",{"date":120,"type":21},"2027-06-13",{"name":122,"class":69},"Assistance Publique - Hôpitaux de Paris",3,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":148,"locationsCount":44},"100594513","efficacy-and-safety-of-huanjingjian-decoction-in-women-with-premature-ovarian-insufficiency-100594513","NCT07020429","Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency","Efficacy and Safety of the Traditional Chinese Herbal Formula Huanjingjian Decoction in Women With Premature Ovarian Insufficiency: a Randomised Controlled Trial","EAST-HOPE","Inclusion Criteria:\n\n* Age between 18 and 39 years\n* Meet the diagnostic criteria for Premature Ovarian Insufficiency (POI) according to the 2024 ESHRE Guideline on Premature Ovarian Insufficiency\n\nExclusion Criteria:\n\n* Menstrual disorders attributable to congenital gonadal dysgenesis or acquired structural pathologies;\n* Menstrual irregularities secondary to endocrine disorders, including polycystic ovary syndrome (PCOS), hyperprolactinemia, dysfunctional uterine bleeding (DUB), gonadal hormone deficiency, hyperthyroidism, and other related endocrine conditions;\n* Oligomenorrhea or amenorrhea induced by surgical or medical interventions, such as chemotherapy, pelvic radiotherapy, ovarian cystectomy, ovarian drilling, ovarian wedge resection, salpingectomy, tubal ligation, pelvic abscess surgery, or uterine artery embolization;\n* History of abnormal vaginal bleeding accompanied by clinically significant findings on endometrial biopsy, or unexplained irregular vaginal bleeding within the preceding 12 months;\n* Suspected cervical malignancy or precancerous cervical lesions, suspected malignant breast tumors, or a known or suspected history of hormone-dependent tumors or malignancies;\n* Previous or current history of deep vein thrombosis (DVT), pulmonary embolism, thrombotic disorders, or cerebrovascular events (stroke);\n* Presence of uncontrolled and\u002For undiagnosed systemic diseases that could confound study results or compromise patient safety, including severe hepatic, renal, cardiac, or neurological disorders;\n* Known hypersensitivity or allergy to any study-related medications;\n* Pregnancy or lactation;\n* Participation in other clinical trials within the last 3 months;\n* Failure or refusal to provide written informed consent.",{"count":133,"type":21},276,[106],"Study Summary\n\nThis clinical trial aims to evaluate the efficacy and safety of the traditional Chinese herbal formula Huanjingjian decoction in women with premature ovarian insufficiency (POI). The study is designed to address the following key questions:\n\n1. Does Huanjingjian decoction improve clinical symptoms in patients with POI?\n2. What adverse medical events, if any, occur during the treatment with Huanjingjian decoction? To answer these questions, researchers will compare Huanjingjian decoction plus hormone replacement therapy (HRT) with placebo plus HRT, in order to determine whether Huanjingjian decoction provides additional therapeutic benefits in the management of POI.\n\nParticipants will:\n\nReceiving either Huanjingjian decoction plus HRT, or placebo plus HRT. Attending monthly clinic visits over a 6-month period for clinical assessments and laboratory testing.\n\nKeeping a detailed diary to record symptoms, treatment adherence, and menstrual flow, as measured by the number of sanitary pads used.",[27],[138,139,140,141],"premature ovarian insufficiency","menopause","traditional Chinese herbal formula","Huanjingjian decoction","2025-09-01",{"date":144,"type":36},"2025-09-08",{"date":142,"type":21},{"date":147,"type":21},"2030-07-30",{"name":149,"class":69},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":102,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":44},"100601791","phase-1-clinical-study-on-the-safety-and-efficacy-of-human-amniotic-mesenchymal-stem-cells-in-the-treatment-of-premature-ovarian-insufficiency-100601791","NCT07115082","Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency","A Randomized, Open-label, Parallel-controlled Clinical Study of Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency","Inclusion Criteria:\n\n1. The intention of pregnant women aged \\>= 20 and \\\u003C 40, with normal karyotype;\n2. Oligo\u002Famenorrhea for at least 4 months;\n3. Elevated FSH level \\>25 IU\u002Fl on two occasions \\>4 weeks apart;\n4. Without a history of stem cell therapy and no growth hormone and\u002For estrogen and progesterone therapy within the previous 3 months;\n5. Voluntary participation in the study with signed informed consent;\n\nExclusion Criteria:\n\n1. Unable to follow the treatment observation process required by the trial;\n2. Genetic diseases, chromosomal abnormalities, and genetic deficiency that clearly cause premature ovarian insufficiency\u002Fpremature ovarian failure;\n3. With breast, uterine, ovarian tumors, or any other benign or malignant tumors;\n4. Allergic history to drugs or any other things;\n5. Presence of genetic disorders such as Turner's syndrome, congenital malformations of the reproductive organs.\n6. Have undergone ovariectomy or have organic gynaecological diseases.\n7. Presence of other gynaecological endocrine diseases such as polycystic ovary syndrome.\n8. Severe functional impairment of vital organs.\n9. High risk factors for venous thromboembolism and abnormalities in coagulation mechanisms.\n10. Attending doctor considers inappropriate to take part in.","20 Years",{"count":159,"type":21},50,[161,162],"PHASE1","PHASE2","There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.",[27],[166,110],"hA-MSCs","2025-08-04",{"date":169,"type":36},"2025-08-11",{"date":171,"type":36},"2024-10-15",{"date":173,"type":21},"2026-03-30",{"name":175,"class":69},"Yan Hongli",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":15,"sex":16,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":44},"100539338","treatment-of-premature-ovarian-insufficiency-using-bone-marrow-cells-100539338","NCT06302543","Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells","Treatment of Premature Ovarian Insufficiency Using Autologous Bone Marrow Concentrates Through Transvaginal Approach Under Ultrasound Guidance","alfarah","Inclusion Criteria:\n\n1. clinical diagnosis of premature Ovarian insufficiency.\n2. ineffective hormonal therapy.\n3. biochemical evidence of high gonadotropins.\n\nExclusion criteria:\n\n1. solid or hematological malignancies.\n2. bleeding disorders.\n3. rejection of the procedure.","30 Years","60 Years",{"count":187,"type":21},10,[106],"investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-Mullerian hormone.\n\nAutologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program.",[27],[192],"premature ovarian failure,bone marrow,treatment","2025-08-02",{"date":195,"type":36},"2025-08-05",{"date":197,"type":36},"2024-03-01",{"date":199,"type":21},"2026-03-10",{"name":201,"class":202},"abdulmajeed hammadi","INDUSTRY",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100577112","therapeutic-effect-of-vitamin-c-supplementation-in-patients-with-ovarian-aging-100577112","NCT06794060","Therapeutic Effect of Vitamin C Supplementation in Patients With Ovarian Aging","Therapeutic Effect of Vitamin C Supplementation in Patients With Ovarian Aging：a Multicenter, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Regularity of menstruation changed for less than one year.\n* 10U\u002FL≤ FSH\\\u003C25 U\u002FL in two tests more than 4weeks aprt.\n* AMH \\\u003C 1.1 ng\u002FmL.\n* Bilateral ovarian AFC \\\u003C7.\n* Signed informed consent and can participate in regular follow-ups.\n\nExclusion Criteria:\n\n* Ovarian aging caused by TUNER (X deletion) syndrome or gene mutation.\n* Ovarian aging caused by ovarian surgery or chemotherapy.\n* Patients with severe endocrine system diseases (diabetes, thyroid disease), digestive system diseases (affecting VC absorption), cardiovascular system diseases, renal insufficiency (abnormal urine, imaging diagnosis, blood, pathological analysis confirms that kidney damage does exist, or glomerular filtration rate GFR \\\u003C60mL\u002Fmin), nervous system diseases such as dementia and epilepsy; patients with infectious diseases such as HIV, hepatitis, tuberculosis; patients with severe autoimmune diseases.\n* Continuous alcohol or drug abuse (to avoid adverse reactions caused by drinking).\n* Allergic to vitamin C or any component of the preparation.\n* Patients who have already started large-dose (greater than 500mg\u002Fday) vitamin C supplementation.\n* Unwilling to or stop taking supplements not provided by this project.\n* Those who have participated in other ovarian aging clinical intervention projects.",{"count":211,"type":21},354,[106],"The goal of this clinical trial is to learn if Vitamin C works to improve ovarian reserve in women with ovarian aging. It will also learn about the safety of Vitamin C. The main questions it aims to answer are:\n\n* Does Vitamin C supplementation improve the ovarian reserve prediction score?\n* What medical problems do participants have when taking Vitamin C supplementation?\n\nResearchers will compare Vitamin C to a placebo (a look-alike substance that contains no drug) to see if drug Vitamin C works to improve ovarian reserve in women with ovarian aging. Participants will:\n\n* Take Vitamin C or a placebo every day for 12 months\n* Visit the clinic once every 4 weeks for follow-up and drug distribution.\n* Return the Vitamin C box at each visit.\n* Report any adverse effects of treatment to the doctor.\n* Fill out a questionnaire at each visit.\n* After 6 months and 12 months of intervention, take blood test and ultrasonic examination.",[27,215],"Ovarian Reserve Function","2025-06-23",{"date":218,"type":36},"2025-06-26",{"date":220,"type":21},"2025-07-02",{"date":222,"type":21},"2027-08-31",{"name":224,"class":69},"Peking University Third Hospital",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":44},"100505204","clinical-application-of-serum-anti-mllerian-hormone-amh-measurements-100505204","NCT05858307","Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements","Inclusion Criteria:\n\n* Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI\n* Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment\n\nExclusion Criteria:\n\n* Women with age \\\u003C10 or ≥45\n* Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion","44 Years",{"count":233,"type":21},300,"This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following:\n\n1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS.\n2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI.\n3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment.\n4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment.\n5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.",[236,237,27,238],"Anti-Müllerian Hormone","Polycystic Ovarian Syndrome","Fertility Issues",[240,237,27,241,242,243,244,245,50],"Anti-Müllerian hormone","Assisted Reproductive Technology treatment","Predictive value","Reproductive outcomes","AMH","PCOS","2025-03-26",{"date":248,"type":36},"2025-03-27",{"date":250,"type":36},"2022-06-22",{"date":66,"type":21},{"name":253,"class":69},"Chinese University of Hong Kong",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":79,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":266,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100574057","phase-1-the-study-of-human-chorionic-gonadotropin-hcg-activating-the-dormant-follicles--100574057","NCT06754332","The Study of Human Chorionic Gonadotropin (HCG) Activating the Dormant Follicles .","The Research on the Role of Human Chorionic Gonadotropin (HCG) Activation in Vivo on the Dormant Follicles in Patients With Premature Ovarian Insufficiency (POI).","Inclusion Criteria:\n\n1. Females under 40 years of age with amenorrhea or oligomenorrhea for at least four months, and elevated follicle-stimulating hormone (FSH) levels \\> 25 IU\u002Fl on two separate occasions (with a 4-week interval);\n2. Ultrasound (B-mode) indicating no antral follicle development in both ovaries for at least 3 months prior to study participation;\n3. Those who agree to participate in this study and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Individuals over 40 years of age, or under 40 years of age with regular menstruation, normal ovulation, amenorrhea or oligomenorrhea for less than 4 months, and elevated follicle-stimulating hormone (FSH) levels \\\u003C 25 IU\u002Fl on two or more separate occasions (with a 4-week interval);\n2. Those with contraindications to the use of injectable human chorionic gonadotropin (HCG);\n3. Those with asthma, epilepsy, heart disease, migraines, renal impairment, hypertension, or other diseases;\n4. Patients deemed by the researcher as otherwise unsuitable for participation in this study.\"",{"count":262,"type":21},60,[161],"This project aims to activate dormant follicles in patients with premature ovarian insufficiency by injecting human chorionic gonadotropin (hCG) to explore the feasibility of a treatment plan that stimulates the growth of dormant follicles, not visible to the naked eye, to antral follicles visible under ultrasound, without visible follicle growth. The project also seeks to enable patients to conceive offspring carrying their own genetic material through in vitro fertilization (IVF) technology.",[27],[50,267,268],"HCG","dormant follicles","2025-03-11",{"date":271,"type":36},"2025-03-12",{"date":273,"type":21},"2025-04-01",{"date":275,"type":21},"2029-08-31",{"name":277,"class":69},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":79,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100582721","exploratory-clinical-study-on-the-efficacy-and-safety-of-lactobacillus-johnsonii-in-the-treatment-of-patients-with-premature-ovarian-insufficiency-100582721","NCT06866990","Exploratory Clinical Study on the Efficacy and Safety of Lactobacillus Johnsonii in the Treatment of Patients with Premature Ovarian Insufficiency","Inclusion Criteria:\n\n1. Age between 20 and 39 years;\n2. Irregular menstruation or amenorrhea for \\> 4 months;\n3. At least two serum baseline follicle-stimulating hormone (FSH) levels \\> 25 IU\u002FL (with an interval of more than 4 weeks between measurements);\n4. Willing to voluntarily participate in this study, sign the informed consent form, and comply with the investigation and follow-up;\n5. Not having participated in other clinical trials within the past 3 months.\n\nExclusion Criteria:\n\n1. Use of antibiotics or probiotics, prebiotics, and live bacterial preparations within the past month or during the intervention period;\n2. Received hormone replacement therapy within the past 2 months;\n3. Chromosomal abnormalities and genetic defects;\n4. Iatrogenic premature ovarian insufficiency;\n5. Stage IV endometriosis;\n6. Uncontrolled endocrine diseases or autoimmune diseases;\n7. Organic gastrointestinal diseases;\n8. Infectious diseases of the reproductive, urinary, or digestive systems;\n9. Severe cardiovascular, respiratory, renal, hematologic, endocrine, neurological, psychiatric, or other systemic diseases that the investigator believes may interfere with the study evaluation;\n10. History of venous thromboembolism;\n11. Allergic or intolerant to the components of the investigational probiotic product;\n12. Allergic to two or more types of food\u002Fmedications;\n13. Refusal to provide written informed consent;\n14. Other conditions deemed unsuitable for participation in the study by the investigator.",{"count":262,"type":21},[106],"The goal of this clinical trial is to explore the effectiveness and safety of Lactobacillus johnsonii in improving ovarian function and perimenopausal symptoms in patients with premature ovarian insufficiency (POI). The main questions it aims to answer are: ① To explore the effectiveness and safety of Lactobacillus johnsonii in improving ovarian function and perimenopausal symptoms in patients with POI; ② To explore the potential mechanism of action of Lactobacillus johnsonii in improving ovarian function and perimenopausal symptoms in patients with POI. Participants who meet all the inclusion criteria will be enrolled in the study and randomly assigned in a 1:1 ratio to either the Lactobacillus johnsonii group or the placebo group.",[27],"2025-03-05",{"date":290,"type":36},"2025-03-10",{"date":292,"type":21},"2025-03",{"date":294,"type":21},"2027-08",{"name":296,"class":69},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":44},"100565684","application-of-platelet-rich-plasma-prp-in-reproductive-medicine-100565684","NCT06645379","Application of Platelet-rich Plasma (PRP) in Reproductive Medicine","Inclusion Criteria:\n\n* Premature ovarian insufficiency: ① Women aged \\>18 and \\\u003C40 years old; ② Oligomenorrhea or amenorrhea for more than 4 months (excluding pregnancy); ③ Basal follicle stimulating hormone (FSH) \\>25IU\u002FL (interval \\>4 weeks) at least 2 times, or total antral follicles (AFC) \\\u003C5, or anti-Mullerian hormone (AMH) \\\u003C1.1ng\u002FmL.\n* Poor ovarian response: ① Advanced age (≥40 years) or other risk factors for poor ovarian response; ② Poor ovarian response in previous IVF cycle, with ≤3 oocytes retrieved using conventional protocols; ③ Decreased ovarian reserve (antral follicle count \\\u003C5\\~7 or anti-Müllerian hormone \\\u003C0.5\\~1.1 ug\u002FL). Meeting any 2 of the above 3 criteria is sufficient.\n* Intrauterine adhesion: ① Diagnosed by hysteroscopy and scored ≥5 points according to the American Fertility Society criteria (1988); ② With symptoms such as reduced menstrual flow amenorrhea, periodic lower abdominal pain, infertility, or recurrent miscarriage; ③ Adult women with the desire to conceive.\n* Thin endometium: ①Endometrial thickness \\\u003C7mm on ovulation day or on the day of human chorionic gonadotropin (HCG) injection, or \\\u003C7mm on progesterone conversion day when using conventional hormone replacement therapy, ②adult women with the desire to comceive.\n* Repeated implantation failure: Women under 40 years old who have failed to achieve clinical pregnancy after transplanting at least three high-quality embryos within three fresh or frozen cycles. High-quality embryos include: Day 3 embryos (with ≥8 cells, evenly sized blastomeres, and \\\u003C10% fragmentation) and blastocysts (≥3BB).\n\nExclusion Criteria:\n\n* Alanine aminotransferase \\> 3 times the normal upper limit or estimated glomerular filtration rate (EGFR) \\\u003C 90 ml\u002Fmin;\n* Suffering from hemorrhagic diseases (such as hemophilia) or taking anticoagulant or antiplatelet drugs;\n* Suffering from serious mental illness, cardiovascular and cerebrovascular diseases and malignant tumors;\n* Suffering from diabetes with poor blood sugar control or other systemic diseases;\n* Drug abuse, alcoholism or drug addiction;\n* Participated in other interventional clinical studies within half a year;\n* Poor compliance;\n* Other circumstances that are not suitable for participating in the study.","50 Years",{"count":233,"type":21},[106],"Female fertility is affected by many factors, such as ovarian function, fallopian tube patency, uterine environment, and mental state, among which the ovaries and endometrium are more important. In reproductive medicine, ovarian dysfunction, poor ovarian reaction, intrauterine adhesion, recurrent implantation failure, and thin endometrium are the five most common diseases that affect fertility. These five diseases lack effective treatment, and previous studies have shown that platelet-rich plasma is promising in treating these five diseases, so it is necessary to further explore the therapeutic effect and potential mechanism.",[27,308,309,310,311],"Intrauterine Adhesion","Poor Ovarian Response","Repeated Implantation Failure","Thin Endometrium","2025-02-14",{"date":314,"type":36},"2025-02-18",{"date":316,"type":36},"2024-10-17",{"date":318,"type":21},"2027-09-15",{"name":277,"class":69},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":15,"sex":16,"minAge":78,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":44},"100523521","the-correlation-between-ovarian-function-and-serum-biomarkers-100523521","NCT06096766","The Correlation Between Ovarian Function and Serum Biomarkers","Study on the Correlation Between Ovarian Function and Serum Biomarkers","Inclusion Criteria:\n\n1. The selection criteria for healthy individuals are follows.\n\n   * women aged 18-45.\n\n     * Basic FSH\\\u003C10IU\u002FL, and AMH is within the normal range.\n\n       * Regular menstruation.\n\n         * Agree and sign an informed consent form.\n2. The selection criteria for DOR patients are follows.\n\n   * women aged 18-45.\n\n     * For two consecutive menstrual cycles, 25 ≥ basal FSH ≥ 10IU\u002FL or AMH\\\u003C1.1ng\u002Fml.\n\n       * Agree and sign an informed consent form.\n3. Selection criteria for POI patients are follows.\n\n   * 18 ≤ females aged \\\u003C40 years old.\n\n     * Two consecutive menstrual cycles with basal FSH\\>25IU\u002FL or AMH\\\u003C1.1ng\u002Fml.\n\n       * Agree and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with congenital gonadal developmental abnormalities or a family history similar to \"early menopause\".\n2. Patients with acquired organic lesions or decreased ovarian function caused by ovarian surgery.\n3. Patients who have undergone artificial cycle therapy with Western medicine or other endocrine treatments within the past three months.\n4. Patients with severe primary diseases and mental disorders such as crdiovascular, cerebrovascular, liver, kidney, and hematopoietic system.\n5. Patients during lactation or pregnancy.\n6. Patients who are allergic to the drugs used in this study or have a history of allergic reactions to traditional Chinese medicine.\n\nThose who meet any of the above 5 criteria for DOR and POI will be excluded and not included in this study. The exclusion criteria for healthy subjects are as (1), (3), (4), and (5).","45 Years",{"count":329,"type":21},35,"The goal of this observational study is to find differences in serum biomarkers between ovarian function and normal individuals.",[27,332,333,334,335,336],"Diminished Ovarian Reserve","Biomarker","Copper","Ceruloplasmin","Aging","2024-12-04",{"date":339,"type":36},"2024-12-09",{"date":341,"type":36},"2023-10-25",{"date":343,"type":21},"2025-11-11",{"name":345,"class":69},"Shi Yun",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":79,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":44},"100553121","application-of-autologous-adipose-stromal-vascular-fraction-in-the-treatment-of-premature-ovarian-insufficiency-100553121","NCT06481969","Application of Autologous Adipose Stromal Vascular Fraction in the Treatment of Premature Ovarian Insufficiency","aSVF-POI","Inclusion Criteria:\n\n* Women aged ≥20 and ≤39 years who have childbearing requirements.\n* Cessation of menstruation or oligomenorrhea for at least 4 months\n* Serum level of basal follicle stimulating hormone (FSH) \\>25 U\u002FL at least 2 times (during the second to fourth day of the menstrual cycle or during amenorrhea; The interval between the two tests is 4 weeks)\n* Serum level of Anti-Mullerian hormone (AMH) ≤1.1 ng\u002Fml\n* Women with intact uterus and bilateral adnexa.\n* Voluntary participation and informed consent obtained.\n\nExclusion Criteria:\n\n* Women with autoimmune diseases.\n* Women with abnormal and uncontrolled thyroid function.\n* Women with tumors in bilateral adnexa that are not clearly benign or malignant.\n* Women with a history of malignant tumors, radiation therapy or chemotherapy.\n* Women with a history of venous thrombosis or pulmonary embolism during the screening period.\n* Women with severe illnesses that are not suitable for pregnancy, such as diseases of the circulatory system, urinary system, digestive system, endocrine system, respiratory system, immune system, mental or neurological system, etc.\n* Women who continuously used systemic glucocorticoids or other immunosuppressants for≥3 weeks within 6 months before administration and women who used systemic glucocorticoids (prednisone≥20 mg\u002Fd or equivalent dose) or other immunosuppressants within 3 days before administration.\n* Women who are allergic to the active ingredients or excipients of test drugs.\n* Women with a family history of severe genetic diseases or gynecologic malignancies.",{"count":354,"type":21},260,[106],"A single-center, prospective, randomised controlled clinical trial (1:1 treatment ratio), designed to investigate the efficacy and safety of autologous SVF in improving the pregnancy outcome of infertile patients with POI.",[27],[359,27,360],"Female fertility","Adipose stromal vascular fraction","2024-11-12",{"date":363,"type":36},"2024-11-14",{"date":365,"type":36},"2024-07-23",{"date":367,"type":21},"2026-12-30",{"name":369,"class":69},"Rui Yang",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":50,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":377,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":44},"100542178","the-bone-metabolism-characteristics-of-premature-ovarian-insufficiency-100542178","NCT06339489","The Bone Metabolism Characteristics of Premature Ovarian Insufficiency","Explore the Bone Metabolism Characteristics of Premature Ovarian Insufficiency","Inclusion Criteria:\n\nPatients diagnosed by Western medicine with premature ovarian insufficiency. 18 ≤ patients' age ≤ 39 years;. Patients who voluntarily participate in this study, sign an informed consent form.\n\nExclusion Criteria:\n\nPatients with congenital gonadal dysplasia or a family history similar to \"early menopause\".\n\nPOI patients with acquired organic lesions or ovarian surgery. Patients who have taken Western or herbal medicine artificial cycle therapy or other endocrine therapy in the past three months.\n\nPatients with serious primary diseases and mental disorders such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system.\n\nPatients who are breastfeeding or pregnant.",{"count":262,"type":21},"Explore the bone metabolism characteristics of premature ovarian insufficiency.",[27,380,381],"Bone Diseases, Metabolic","Bone Mineral Density","2024-06-21",{"date":384,"type":36},"2024-06-25",{"date":386,"type":36},"2024-04-01",{"date":388,"type":21},"2025-02-01",{"name":345,"class":69}]